Robert Bloder

Robert Bloder has a strong and extensive work experience in the pharmaceutical industry. Robert is currently serving as the Chief Business Officer at Ascendia since January 2019. Before that, they were the President of RPM Pharma Consulting, Inc. from March 2018 onwards.

Prior to that, Bloder held several leadership positions at Apotex Inc., starting as the Vice President of Business Development in April 2014. Robert successfully built a global departmental culture and guided talented teams towards exceeding corporate goals. Robert also played a key role in migrating Aveva products and contracts to Apotex. Bloder transitioned the co-development team from R&D to business development and identified products with unique drug delivery and manufacturing technologies. Robert served as the Vice President of Co-Development and Vice President of Global Business Development during their tenure at Apotex.

Bloder was a Board Member and Vice President of Business Development at Aveva Drug Delivery Systems from 2003 to 2014. Robert focused on growing the company's revenue and assets through marketing, contracts, licensing, acquisitions, and global expansion.

Prior to that, Bloder co-founded ESP Pharma (now Protein Design Labs) and served as the Vice President of Market Development from 2000 to 2003. At ESP Pharma, they identified market needs and developed business plans to increase revenues.

Bloder began their career at Pfizer in 1989 and held various roles of increasing responsibility in marketing, sales, and business development. Robert launched and led the nation with numerous blockbuster products, including Lipitor and Neurontin.

Overall, Robert Bloder has demonstrated expertise in business development, strategic partnerships, market development, and leadership in the pharmaceutical industry.

Robert Bloder's education history includes a Bachelor of Science degree from Bethany College. No specific details regarding the duration or field of study were provided.